Analytical methods knowledge base
LC–MS Identity Testing for Peptides
How intact-mass evidence, charge-state deconvolution, chromatographic separation and orthogonal confirmation contribute to a defensible peptide identity assessment.
Method-aware interpretation
Read the result as a chain of evidence.
Each section connects the analytical question, reporting basis and conclusion boundary.
What intact mass answers
LC–MS can show whether a chromatographic component produces ions consistent with an expected molecular mass. For multiply charged peptides, the reported neutral mass is commonly calculated from a charge-state envelope. The comparison should state whether the expected value is monoisotopic or average mass and whether the reported material includes a modification.
- Match the mass convention used in the specification and report.
- Inspect the charge-state envelope and deconvolution settings when available.
- Document tolerated mass error in units appropriate to the instrument and intended purpose.
Why a matching mass is not a full sequence proof
Different sequences or positional isomers can share the same nominal or exact mass. Intact mass also may not localize a modification or exclude every low-level impurity. Sequence-sensitive fragmentation, amino-acid analysis or other orthogonal evidence may be needed when the decision requires more than intact molecular mass.
- Do not convert “mass consistent with” into “complete sequence confirmed” unless the evidence supports that wording.
- Check whether the mass signal corresponds to the main chromatographic component.
- Distinguish identity testing from impurity profiling and quantitative assay.
Read the report as an analytical chain
A useful LC–MS report connects sample identity, acquisition date, chromatographic trace, mass spectrum, processing method, expected mass, observed mass and analyst conclusion. Screenshots without sample identifiers or processing context are weaker than a traceable report.
- Confirm the lot or sample identifier appears on the report.
- Check for salt, adduct, oxidation or truncation annotations rather than assuming every extra signal is unexplained.
- Request the method scope when a pass/fail conclusion is material to procurement.
Decision table
What the field means—and what it does not prove
Use this table to prevent a valid analytical result from being expanded beyond its intended purpose.
↔ Swipe horizontally to read every column
| Record or question | What it can support | What it does not prove |
|---|---|---|
| Observed mass matches expected? | Supports intact molecular-mass consistency | Complete amino-acid sequence or biological activity |
| LC separation precedes MS? | Links mass signals to separated components | Absolute content of the bulk material |
| Fragmentation evidence included? | Can add sequence-localizing information | Purity, sterility or endotoxin status |
Interpretation limits
Stop where the method stops.
- Mass accuracy must be interpreted against instrument capability and method purpose.
- Counterions often are not represented by the deconvoluted peptide mass.
- Catalog and approved-drug identity are separate questions even when the named active sequence is similar.
Primary and technical sources
Records used for this guide
Sources are linked directly so the wording, date and scope can be checked independently.
- 01Source record
ICH Q2(R2): Validation of Analytical Procedures
International Council for Harmonisation. Step 4, adopted November 2023; error-corrected 2025.
- 02Source record
Analytical Procedures and Methods Validation for Drugs and Biologics
U.S. Food and Drug Administration. Guidance for Industry, July 2015.
- 03Source record
Reference Standards to Support Quality of Synthetic Peptide Therapeutics
Manning MC, et al. AAPS Journal. 2023;25:67. PMCID: PMC10338602.
Knowledge center